ORA 16th Annual General MeetingMore
We look forward to seeing you at the ORA 16th Annual General Meeting May 26-28, 2017!
Retreatment with Rituximab (Rituxan) through EAP.
EAP will now approve Rituximab renewals in advance of loss of effect/flare.
Good News on EAP Approvals!
The ORA EAP Committee recently met with the governement to discuss lengthy EAP approval timelines. Immediate action steps have been taken. Read more
- EAP Update: Unacceptable Approval Timelines
- View All News
2016 ORA Residents’ Weekend
June 24-25, 2016, Chelsea Hotel, Toronto, Ontario
The ORA is proud to support the Annual Residents’ Weekend - a unique and immersive educational opportunity for rheumatology residents in Ontario.
16th Annual General Meeting
May 26-28, 2017, JW Marriott Lake Rosseau Resort
Join us in Muskoka for the ORA’s 16th Annual General Meeting
- View All Events
Diamond: Pfizer Canada Inc., Amgen Canada Inc., Celgene Inc., AbbVie Canada, UCB Canada Inc., Novartis Canada
Platinum: Janssen Inc., Eli Lilly, Bristol-Myers Squibb Canada
Gold: Hospira, Roche Canada,
Silver: Medexus Inc., Merck, Sanofi
Specialty Pharmacy: Sobi, Bedrocan